{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:51:50Z","timestamp":1792165910154,"version":"4.4.0"},"reference-count":20,"publisher":"American Association for Cancer Research (AACR)","issue":"4","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,2,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To evaluate the clinical efficacy of monoclonal antibody (mAb) 3E10 Fv antibody-mediated p53 protein therapy, an Fv-p53 fusion protein produced in Pichia pastoris was tested on CT26.CL25 colon cancer cells in vitro and in vivo in a mouse model of colon cancer metastasis to the liver. In vitro experiments showed killing of CT26.CL25 cells by Fv-p53 but not Fv or p53 alone, and immunohistochemical staining confirmed that Fv was required for transport of p53 into cells. Prevention of liver metastasis in vivo was tested by splenic injection of 100 nmol\/L Fv-p53 10 min and 1 week after injection of CT26.CL25 cancer cells into the portal vein of BALB\/c mice. Mice were sacrificed 1 week after the second injection of Fv-p53 and assigned a quantitative metastasis score. Control mice had an average metastasis score of 3.3 \u00b1 1.3, whereas mice treated with Fv-p53 had an average metastasis score of 0.8 \u00b1 0.4 (P = 0.004). These results indicate that Fv-p53 treatment had a profound effect on liver metastasis and represent the first demonstration of effective full-length p53 protein therapy in vivo. mAb 3E10 Fv has significant clinical potential as a mediator of intracellular and intranuclear delivery of p53 for prevention and treatment of cancer metastasis. [Cancer Res 2007;67(4):1769\u201374]<\/jats:p>","DOI":"10.1158\/0008-5472.can-06-3783","type":"journal-article","created":{"date-parts":[[2007,2,16]],"date-time":"2007-02-16T18:42:18Z","timestamp":1171651338000},"page":"1769-1774","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Antibody-Mediated p53 Protein Therapy Prevents Liver Metastasis<i>In vivo<\/i>"],"prefix":"10.1158","volume":"67","author":[{"given":"James E.","family":"Hansen","sequence":"first","affiliation":[{"name":"1Veterans Affairs Greater Los Angeles Healthcare System, Sepulveda, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurice K.","family":"Fischer","sequence":"additional","affiliation":[{"name":"2Loma Linda Veterans Affairs Medical Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Chan","sequence":"additional","affiliation":[{"name":"1Veterans Affairs Greater Los Angeles Healthcare System, Sepulveda, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia S.","family":"Chang","sequence":"additional","affiliation":[{"name":"1Veterans Affairs Greater Los Angeles Healthcare System, Sepulveda, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott W.","family":"Baldwin","sequence":"additional","affiliation":[{"name":"2Loma Linda Veterans Affairs Medical Center;"},{"name":"3Loma Linda University, Loma Linda, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Aragon","sequence":"additional","affiliation":[{"name":"2Loma Linda Veterans Affairs Medical Center;"},{"name":"3Loma Linda University, Loma Linda, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline J.","family":"Carter","sequence":"additional","affiliation":[{"name":"2Loma Linda Veterans Affairs Medical Center;"},{"name":"3Loma Linda University, Loma Linda, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lilly","sequence":"additional","affiliation":[{"name":"3Loma Linda University, Loma Linda, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert N.","family":"Nishimura","sequence":"additional","affiliation":[{"name":"1Veterans Affairs Greater Los Angeles Healthcare System, Sepulveda, California;"},{"name":"4Olive View-University of California at Los Angeles Medical Center, Sylmar, California; and"},{"name":"5University of California at Los Angeles David Geffen School of Medicine, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard H.","family":"Weisbart","sequence":"additional","affiliation":[{"name":"1Veterans Affairs Greater Los Angeles Healthcare System, Sepulveda, California;"},{"name":"4Olive View-University of California at Los Angeles Medical Center, Sylmar, California; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Reeves","sequence":"additional","affiliation":[{"name":"2Loma Linda Veterans Affairs Medical Center;"},{"name":"3Loma Linda University, Loma Linda, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2007,2,16]]},"reference":[{"key":"2022061623230765200_B1","doi-asserted-by":"crossref","unstructured":"Vousden KH. p53: death star. Cell\u20082000; 103: 691\u20134.","DOI":"10.1016\/S0092-8674(00)00171-9"},{"key":"2022061623230765200_B2","unstructured":"Nielsen LL, Maneval DC. p53 tumor suppressor gene therapy for cancer. Cancer Gene Ther\u20081998; 5: 52\u201363."},{"key":"2022061623230765200_B3","doi-asserted-by":"crossref","unstructured":"Kodama K, Katayama Y, Shoji Y, Nakashima H. The features and shortcomings for gene delivery of current non-viral carriers. Curr Med Chem\u20082006; 13: 2155\u201361.","DOI":"10.2174\/092986706777935276"},{"key":"2022061623230765200_B4","doi-asserted-by":"crossref","unstructured":"Ryu J, Lee HJ, Kim KA, et al. Intracellular delivery of p53 fused to the basic domain of HIV-1 Tat. Mol Cells\u20082004; 17: 353\u20139.","DOI":"10.1016\/S1016-8478(23)13050-0"},{"key":"2022061623230765200_B5","unstructured":"Takenobu T, Tomizawa K, Matsushita M, et al. Development of p53 protein transduction therapy using membrane-permeable peptides and the application to oral cancer cells. Mol Cancer Ther\u20082002; 1: 1043\u20139."},{"key":"2022061623230765200_B6","doi-asserted-by":"crossref","unstructured":"Weisbart RH, Hansen JE, Chan G, et al. Antibody-mediated transduction of p53 selectively kills cancer cells. Int J Oncol\u20082004; 25: 1867\u201373.","DOI":"10.3892\/ijo.25.6.1867"},{"key":"2022061623230765200_B7","doi-asserted-by":"crossref","unstructured":"El-Amine M, Hinshaw JA, Scott DW. In vivo induction of tolerance by an Ig peptide is not affected by the deletion of FvR or a mutated IgG Fc fragment. Int Immunol\u20082002; 14: 761\u20136.","DOI":"10.1093\/intimm\/dxf049"},{"key":"2022061623230765200_B8","doi-asserted-by":"crossref","unstructured":"Zambidis ET, Scott DW. 1996 Epitope-specific tolerance induction with an engineered immunoglobulin. Proc Natl Acad Sci U S A\u20081996; 93: 5019\u201324.","DOI":"10.1073\/pnas.93.10.5019"},{"key":"2022061623230765200_B9","doi-asserted-by":"crossref","unstructured":"Lai Y, Du L, Dunsmore KE, Jenkins LW, Wong HR, Clark RS. Selectively increasing inducible heat shock protein 70 via TAT-protein transduction protects neurons from nitrosative stress and excitotoxicity. J Neurochem\u20082005; 94: 360\u20136.","DOI":"10.1111\/j.1471-4159.2005.03212.x"},{"key":"2022061623230765200_B10","doi-asserted-by":"crossref","unstructured":"Pu H, Tian J, Flora G, et al. HIV-1 Tat protein upregulates inflammatory mediators and induces monocyte invasion into the brain. Mol Cell Neurosci\u20082003; 24: 224\u201337.","DOI":"10.1016\/S1044-7431(03)00171-4"},{"key":"2022061623230765200_B11","doi-asserted-by":"crossref","unstructured":"Moulton HM, Hase MC, Smith KM, Iversen PL. HIV Tat peptide enhances cellular delivery of antisense morpholino oligomers. Antisense Nucleic Acid Drug Dev\u20082003; 13: 31\u201343.","DOI":"10.1089\/108729003764097322"},{"key":"2022061623230765200_B12","doi-asserted-by":"crossref","unstructured":"Toborek M, Lee YW, Pu H, et al. HIV-Tat protein induces oxidative and inflammatory pathways in brain endothelium. J Neurochem\u20082003; 84: 169\u201379.","DOI":"10.1046\/j.1471-4159.2003.01543.x"},{"key":"2022061623230765200_B13","unstructured":"Weisbart RH, Wakelin R, Chan G, Miller CW, Koeffler PH. Construction and expression of a bispecific single-chain antibody that penetrates mutant p53 colon cancer cells and binds p53. Int J Oncol\u20082004; 25: 1113\u20138."},{"key":"2022061623230765200_B14","doi-asserted-by":"crossref","unstructured":"Weisbart RH, Baldwin R, Huh B, Zack DJ, Nishimura R. Novel protein transfection of primary rat cortical neurons using an antibody that penetrates living cells. J Immunol\u20082000; 164: 6020\u20136.","DOI":"10.4049\/jimmunol.164.11.6020"},{"key":"2022061623230765200_B15","doi-asserted-by":"crossref","unstructured":"Jain A, Slansky JE, Matey LC, Allen HE, Pardoll DM, Schulick RD. Synergistic effect of a granulocyte-macrophage colony-stimulating factor-transduced tumor vaccine and systemic interleukin-2 in the treatment of murine colorectal cancer hepatic metastases. Ann Surg Oncol\u20082003; 10: 810\u201320.","DOI":"10.1245\/ASO.2003.10.006"},{"key":"2022061623230765200_B16","doi-asserted-by":"crossref","unstructured":"Cai SR, Garbow JR, Culverhouse R, et al. A mouse model for developing treatment for secondary liver tumors. Int J Oncol\u20082005; 27: 113\u201320.","DOI":"10.3892\/ijo.27.1.113"},{"key":"2022061623230765200_B17","doi-asserted-by":"crossref","unstructured":"Kasuya H, Kuruppu HK, Donahue JM, Choi EW, Kawasaki H, Tanabe KK. Mouse models of subcutaneous spleen reservoir for multiple portal venous injections to treat liver malignancies. Cancer Res\u20082005; 65: 3823\u20137.","DOI":"10.1158\/0008-5472.CAN-04-2631"},{"key":"2022061623230765200_B18","doi-asserted-by":"crossref","unstructured":"Mehra R, Burtness B. Antibody therapy for early-stage breast cancer: trastuzumab adjuvant and neoadjuvant trials. Expert Opin Biol Ther\u20082006; 6: 951\u201362.","DOI":"10.1517\/14712598.6.9.951"},{"key":"2022061623230765200_B19","unstructured":"Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res\u20081992; 52: 3402\u20138."},{"key":"2022061623230765200_B20","unstructured":"Yokota T, Milenic DE, Whitlow M, Wood JF, Hubert SL, Schlom J. Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms. Cancer Res\u20081993; 53: 3776\u201383. Erratum in: Cancer Res 1993;53:5832."}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/4\/1769\/2578433\/1769.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/4\/1769\/2578433\/1769.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,11]],"date-time":"2024-02-11T00:35:44Z","timestamp":1707611744000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/67\/4\/1769\/534016\/Antibody-Mediated-p53-Protein-Therapy-Prevents"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2,15]]},"references-count":20,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2007,2,16]]},"published-print":{"date-parts":[[2007,2,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-06-3783","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2,15]]}}}